Copyright
©The Author(s) 2019.
World J Gastroenterol. Jul 21, 2019; 25(27): 3607-3618
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3607
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3607
Figure 1 Cumulative survival stratified by Barcelona Clinic Liver Cancer staging in the overall cohort.
BCLC: Barcelona clinic liver cancer.
Figure 2 Characteristics and management of patients treated with transarterial chemoembolization.
A: Kaplan Meier survival curves according to Barcelona Clinic Liver Cancer stage and treatment with/without trans-arterial chemoembolization; B: Survival according to radiological response after the first transarterial chemoembolization (TACE) evaluated by RECIST 1.1 criteria. BCLC: Barcelona clinic liver cancer.
Figure 3 Corresponding survival curves for patients treated with Sorafenib stratified by Barcelona Clinic Liver Cancer stages.
BCLC: Barcelona clinic liver cancer.
Figure 4 Survival in Barcelona Clinic Liver Cancer stage B patients under tumor progression with the sequential treatment of transarterial chemoembolization-sorafenib.
BCLC: Barcelona clinic liver cancer.
- Citation: Piñero F, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Romero G, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Reggiardo V, Colombato L, Gadano A, Silva M. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World J Gastroenterol 2019; 25(27): 3607-3618
- URL: https://www.wjgnet.com/1007-9327/full/v25/i27/3607.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i27.3607